Systems Immunology profiling of respiratory viral infections in vulnerable populations

易感人群呼吸道病毒感染的系统免疫学分析

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT – PROJECT 2 Acute respiratory viral infections (ARVI) are the most frequently occurring global illness producing significant morbidity and mortality, particularly in vulnerable populations. Adults with rheumatoid arthritis (RA) have an increased risk for infection and respiratory mucosal inflammation may contribute to autoimmune disease severity. The goal of this research project is to understand the molecular and cellular immune signatures of the RA response to ARVI to determine how this affects infection severity and autoimmune disease progression. The project includes a detailed systems immunology assessment of acute and long-term airway and adaptive systemic immune responses to naturally occurring ARVI. Project 2 will examine these responses in patients with early RA and established RA on immunosuppression and compare these responses to matched healthy controls. This project is synergistic with the overall program by utilizing similar sample types, timing of sample collection, and common clinical endpoints but differs by studying a distinct host. The individual projects benefit from the overall program's shared multi-omics approaches through a Genomics Core for the samples processing and generation of airway host transcriptome, proteome, epithelial methylation, and viral quantity and expression data, along with host genetics. There is also a shared Adaptive Phenotyping Core for the generation of high dimensional cytometry data to broadly characterize immune cell phenotypes and for detailed identification of antigen-specific cells. The first aim is to determine differences in respiratory innate immune profiles in pre/early RA, established RA, and healthy controls in response to ARVI using a multi-omics approach. The second aim will determine if there are differences in adaptive cellular responses including a detailed characterization of viral-specific and autoantigen specific populations. The third aim will utilize TotalSeq (scRNA-seq, TCR/BCR sequencing and surface protein quantification), to determine the relationship between mucosal and systemic responses. This study will determine both how mucosal inflammation contributes to autoimmune pathogenesis and the host response to ARVI. It will produce novel mechanistic insights into the diversity and commonality of adult and RA immune response to acute respiratory viruses and use cutting-edge methods to provide mechanistic insights.
项目总结/摘要-项目2 急性呼吸道病毒感染(阿尔维)是最常见的全球性疾病, 发病率和死亡率,特别是在弱势群体中。类风湿性关节炎(RA)的治疗方法有哪些? 感染和呼吸道粘膜炎症风险增加可能导致自身免疫性疾病 严重性。该研究项目的目标是了解免疫缺陷病毒的分子和细胞免疫特征。 RA对阿尔维的反应,以确定这如何影响感染的严重程度和自身免疫性疾病的进展。 该项目包括一个详细的系统免疫学评估急性和长期的气道和适应性 对自然发生的阿尔维的全身免疫应答。项目2将检查患者的这些反应 与早期RA和已建立的RA进行免疫抑制,并将这些反应与匹配的健康人进行比较。 对照该项目是协同与整体计划,利用类似的样品类型,样品的时间 收集和共同的临床终点,但通过研究不同的宿主而有所不同。单个项目受益 从整个项目的共享多组学方法,通过基因组学核心的样本 气道宿主转录组、蛋白质组、上皮甲基化和病毒数量的加工和产生 和表达数据,沿着宿主遗传学。还有一个共享的适应性表型核心, 生成高维细胞术数据,以广泛表征免疫细胞表型, 抗原特异性细胞的鉴定。第一个目的是确定呼吸道先天免疫的差异, 使用多组学方法,在前/早期RA、确诊RA和健康对照中对阿尔维的反应谱 approach.第二个目标将确定适应性细胞反应是否存在差异,包括 病毒特异性和自身抗原特异性群体的详细表征。第三个目标是利用 TotalSeq(scRNA-seq、TCR/BCR测序和表面蛋白定量),以确定 粘膜反应和全身反应之间的关系。这项研究将确定粘膜炎症如何 有助于自身免疫发病机制和宿主对阿尔维的应答。它将产生新的机械 深入了解成人和RA对急性呼吸道病毒的免疫反应的多样性和共性, 使用尖端的方法来提供机械的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carmen R Mikacenic其他文献

Carmen R Mikacenic的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carmen R Mikacenic', 18)}}的其他基金

Admin Core
管理核心
  • 批准号:
    10420944
  • 财政年份:
    2022
  • 资助金额:
    $ 31.6万
  • 项目类别:
Systems Immunology profiling of respiratory viral infections in vulnerable populations
易感人群呼吸道病毒感染的系统免疫学分析
  • 批准号:
    10420949
  • 财政年份:
    2022
  • 资助金额:
    $ 31.6万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10598117
  • 财政年份:
    2022
  • 资助金额:
    $ 31.6万
  • 项目类别:
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
急性呼吸窘迫综合征 (IC-ARDS) 中的免疫检查点
  • 批准号:
    10655533
  • 财政年份:
    2020
  • 资助金额:
    $ 31.6万
  • 项目类别:
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
急性呼吸窘迫综合征 (IC-ARDS) 中的免疫检查点
  • 批准号:
    10254220
  • 财政年份:
    2020
  • 资助金额:
    $ 31.6万
  • 项目类别:
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
急性呼吸窘迫综合征 (IC-ARDS) 中的免疫检查点
  • 批准号:
    10434143
  • 财政年份:
    2020
  • 资助金额:
    $ 31.6万
  • 项目类别:
Influence of TLR1 Polymorphisms on T-Regulatory Cells in ARDS
TLR1 多态性对 ARDS 调节性 T 细胞的影响
  • 批准号:
    8865672
  • 财政年份:
    2014
  • 资助金额:
    $ 31.6万
  • 项目类别:
Influence of TLR1 Polymorphisms on T-Regulatory Cells in ARDS
TLR1 多态性对 ARDS 调节性 T 细胞的影响
  • 批准号:
    8616243
  • 财政年份:
    2014
  • 资助金额:
    $ 31.6万
  • 项目类别:
Influence of TLR1 Polymorphisms on T-Regulatory Cells in ARDS
TLR1 多态性对 ARDS 调节性 T 细胞的影响
  • 批准号:
    9271218
  • 财政年份:
    2014
  • 资助金额:
    $ 31.6万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了